Multivalent Glycosylated Nanostructures for Ebola Virus Infection by Illescas, Beatriz M. et al.
Multivalent Glycosylated Nanostructures for Ebola Virus Infection 
Beatriz M. Illescas,*,† Javier Rojo,*,‡ Rafael Delgado,*,§ Nazario Martín.*,† 
nazmar@ucm.es 
† Departamento de Química Orgánica, Facultad de Química, Universidad Complutense, 28040 Madrid, Spain. 
‡ Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), CSIC – Universidad de Sevilla, Av. Américo Vespu-
cio 49, Seville 41092 Spain. 
§ Laboratorio de Microbiología Molecular, Instituto de Investigación Hospital 12 de Octubre (imas12) 28041 Madrid, Spain. 
ABSTRACT: The infection of humans by lethal pathogens such as Ebola and other related viruses has not been properly addressed 
so far. In this context, a relevant question arises: what can chemistry do in the search for new strategies and approaches to solve this 
emergent problem? Although initially a variety of known chemical compounds – for other purposes – have been disappointingly 
tested against Ebola virus infection, more recently, specific molecules have been prepared. In this Perspective, we present a new 
approach directed to the design of efficient entry inhibitors to minimize the development of resistance by viral mutations. In partic-
ular, we focused on dendrimers as well as fullerene C60 – with a unique symmetrical and 3D globular structure – as biocompatible carbon platforms for the multivalent presentation of carbohydrates. The antiviral activity of these compounds in an Ebola pseudo-
typed infection model were in the low micromolar range for fullerenes with 12 and 36 mannoses. However, new tridecafullerenes – 
in which the central alkyne scaffold of [60]fullerene has been connected to 12 sugar-containing [60]fullerene units (total 120 man-
noses)– exhibit an outstanding antiviral activity with IC50 in the subnanomolar range! The multivalent presentation of specific car-bohydrates by using 3D fullerenes as controlled biocompatible carbon scaffolds represents a real advance being currently the most 
efficient molecules in vitro against Ebola virus infection. However, additional studies are needed to determine the optimized fuller-
ene-based leads for practical applications. 
INTRODUCTION 
Ebola virus (EBOV) is among the most lethal pathogens for 
humans. Since its initial description in 1976 in Zaire (now 
DRC), several outbreaks have been reported mainly in Central 
Africa1. EBOV belongs to the Zaire Ebolavirus species within 
the Ebolavirus family where three additional varieties of high-
ly pathogenic agents: Sudan, Tai forest and Bundibugyo virus-
es, have also been described2. There is a fifth variety known as 
Reston virus endemic in certain areas in Asia that apparently is 
not pathogenic for humans3. Although some fruit bats have 
been identified to be carriers of EBOV genetic sequences, still 
the natural reservoirs of EBOV are not clear and this is a cru-
cial information for surveillance and prevention of future 
outbreaks4.  
The recent Ebola outbreak in West Africa (2013-2016) has 
been caused by EBOV and it has been unprecedented in the 
number of infected cases. Thus, over 28000 cases and a toll of 
more than 11000 fatalities have been officially reported5 in the 
main affected area of Guinea, Sierra Leona and Liberia and 
also some cases in neighbor countries such as Nigeria, Mali 
and Senegal. Apart from the devastation in West Africa, this 
outbreak fueled a health emergency of international concern 
since Ebola infected patients travelled or were evacuated out 
of Africa and were treated in USA, UK, Spain, France, Ger-
many, Italy, Switzerland and Norway6.  
There is no specific treatment for EBOV and supportive 
therapy based in treatment of complications and active fluid 
and electrolyte replacement, remained as the basis for patient’s 
management during this outbreak6-7. A variety of experimental 
compounds, such as EBOV specific monoclonal antibodies 
(ZMapp), interference RNA (TKM) or inhibitors of the viral 
RNA polymerase (Brincidofovir, Favipiravir (T-505) and GS-
5734) (Figure 1) have shown therapeutic potential in experi-
mental animal models of infection, rodents and non-human 
primates (NHP). However, thus far none of them has demon-
strated clinical efficacy since they have only been anecdotally 
used in selected patients or in relatively small non-controlled 
clinical trials10.  
At the beginning of the aforementioned last outbreak, there 
were also two prototypes of vaccines to prevent EBOV infec-
tion that had been tested in NHP with encouraging results but 
never used in human beings11. In an accelerated process to 
fulfill the safety and immunogenicity requirements in humans, 
the two vaccines, both virally vectored in chimpanzee adeno-
virus (ChAD) and in vesicular stomatitis virus (VSV), respec-
tively, were ready to be administered in the affected area in 
early 2015, at a time where the epidemic was weaning and 
new cases started to be significantly reduced. Only results of 
efficacy from the VSV-based vaccine are available at this 
moment and, although involving a relative small group of 
individuals, the vaccine showed a 100% protection against 
EBOV when immediately administered to contacts of infected 
patients as compared with a control group that was vaccinated 
with a delay of 3 weeks12. Despite these promising results, 
questions remain on the duration of protection and the poten-
tial coverage against other members of the ebolavirus family 
such as Sudan or Bundibugyo viruses. 
Under this situation, new programs and actions have been 
launched and funded by public institutions and foundations in 
order to speed up the discovery of new and effective drugs as 
soon as possible. However, the output of these strategies has 
 not been completely successful so far. New approaches have 
been addressed and promising compounds are again in the 
pipeline waiting for their evaluation13. Recently, an inhibitor 
of viral RNA polymerase has been developed. This nucleoside 
analog (BCX4430) has shown protection against Ebola as well 
as Marburg viral infection in a rodent model. Moreover, it has 
been demonstrated that this compound also protects non-
human primates even 48 hours administration after exposure 
to Marburg virus infection.8 Phase 1 clinic studies with this 
new promising compounds are ongoing.9 A new approach 
consists on the use of some small molecules that were previ-
ously FDA-approved as drugs for different indications, which 
have now been tested as potential Ebola virus inhibitors.  
These small molecules present very different chemical struc-
tures and mode of actions with different targets in the viral 
infection cycle. Clomiphene and Toremiphene (Figure 1) are 
FDA-approved drugs with a similar structure but different 
indications. Clomiphene is used to treat infertility while 
Toremiphene is approved to treat advanced breast cancer. 
Both are estrogen receptor ligands and are capable to inhibit 
the EBOV entry and internalization in vitro. Recently, it has 
been shown the capacity of these molecules to inhibit Ebola 
infection in a murine Ebola infection model14. 
Another example is the n-butyl-deoxynojirimycin 
(Miglustat), an aminosugar derived of the D-glucose approved 
by the FDA to treat type I Gauche disease (GD1) (Figure 1). 
This is a well-known inhibitor of the enzyme -glycosidase 
and its anti-viral activity by the modification of the N-glycan 
composition of viral envelope glycoproteins has been 
proved15. However, a recent study using these iminosugars as 
inhibitiors of Ebola infection in a guinea pig model showed 
very limited protection16. 
The lack of information on the mechanism of infection, the 
need to use BSL4 laboratories to manipulate the wild virus – 
with the implications in terms of cost and accessibility that this 
means – as well as the scarce chances to carry out clinical 
studies on the ground with infected patients – usually concen-
trated in remote areas in Central Africa – provide a complicat-
ed scenario to progress in this field. In this context, a relevant 
question arises: what can chemistry do in the search for new 
strategies and approaches to achieve some success in this 
emergent problem? Actually, new treatment alternatives are 
desperately needed. 
DC-SIGN AS TARGET MOLECULE 
EBOV has a broad cell tropism although macrophages, 
monocytes and dendritic cells are major targets for infection17. 
There are different possibilities in terms of checkpoints for 
antiviral actions during the infection of EBOV: entry inhibi-
tors; inhibitors of viral replication; suppression of viral assem-
bly and particles release and vaccination (activation of the 
immune system because infected antigen presenting cells are 
not activated by the Ebola virus and they should not be able to 
induce an immunological response).  Among all these strate-
gies, the design of entry inhibitors appears as a good approach 
with the advantage to minimize the development of resistance 
by viral mutations18. Entry inhibitors can be focused on differ-
ent targets involved in the interaction of the envelope viral 
glycoprotein (GP) with cell receptors, membrane fusion, endo-
some formation and viral particles release into the target cell 
cytoplasm.  
 
 
Figure 1. Chemical structures of Brincidofovir, Favipiravir, GS-
5734, Clomiphene, Toremiphene, BCX4430 and Miglustat. 
The GP protein is the sole molecule of EBOV responsible to 
interact with target cells19. In 2002, a new gate for Ebola inva-
sion of cells was discovered, the lectin DC-SIGN. DC-SIGN 
(Dendritic Cells Specific ICAM-3 Grabbing Non-integrin)20 
present at the surface of dendritic cells (DCs) is a lectin of the 
C-type able to recognize in a calcium dependent manner, 
highly glycosylated envelope proteins such as gp120 of HIV 
or GP of Ebola virus21. This lectin facilitates the entrance of 
the virus into DCs, cells presented in mucosal surfaces and 
potentially facilitating viral infection and systemic dissemina-
tion21a. Since its discovery in 2000 and the demonstration of its 
role in the recognition of a large family of pathogens including 
viruses, bacteria, fungi and parasites such as HIV, Ebola, 
Citomegalovirus, Hepatitis C virus, Mycobacterium tuberculo-
sis, Schistosoma, Candida spp, etc., this lectin has been con-
sidered as an universal pathogen receptor and a potential new 
therapeutic target22. This discovery opened the door for the 
development of new antiviral compounds based on carbohy-
drates mimicking the presentation of the glycans presented in 
the viral glycoproteins.  To achieve this aim, a multivalent 
presentation of carbohydrates is required to reach high affini-
ties for this lectin and to compete efficiently with the virus for 
this receptor23. 
Recently, a potential role of DC-SIGN expressing cells has 
been reported in animal models of infection suggesting that, in 
fact, these dendritic cells have a key role in the initial steps of 
EBOV infection and dissemination24. 
CHEMICAL STRUCTRURES 
Several carbohydrate multivalent systems have been devel-
oped and tested as good inhibitors for DC-SIGN-dependent 
viral infections23a. A variety of platforms have been evaluated 
as useful scaffolds for conjugation of carbohydrates to create 
different carbohydrate multivalent systems where the size, 
shape and valency (number of carbohydrates) have been mod-
ulated at will.  
Dendrimers are monodisperse highly branched polymers. 
The stepwise synthesis of dendrimers allows a fine control of 
the structure as well as the physical and chemical properties of 
 the final entities25. The functional groups present at the periph-
ery can be manipulated to modulate these properties. Further-
more, these functional groups can be used for the conjugation 
of ligands, thus creating multivalent systems. In other words, 
dendrimers can be considered as ideal scaffolds for a multiva-
lent presentation of ligands.  
Carbohydrate multivalent systems based on dendrimers 
have been synthesized for the development of molecules capa-
ble to block DC-SIGN26. More than a decade ago, mannosyl-
ated dendritic polymers based on the 2nd and 3rd generations of 
the commercially available Boltorn hyperbranched polymer 
were synthesized27. The good activity of the 3rd generation 
glycodendrimer to inhibit the interaction of pathogens to DC-
SIGN28 opened the door for the development of more active 
compounds using the same scaffold but more sophisticated 
and efficient ligands for DC-SIGN, in particular a pseudo-
mannobiose and a pseudomannotriose29 (Figure 2). These 
glycodendrimers have been prepared in a divergent way, 
building up the dendrimer from the central core to the periph-
ery. As a final step, carbohydrate ligands were conjugated by a 
classical amide formation.  
 
OO
O
O
O
O
O
O
O
O
HN
O
O
NH
OOO
O
O
O
O
NH O
O
HN O
O
O
O
O
O
O
O
O
O
O
NH
OO
HN
O
O
O
O
O
O
O
NH
O
OHN
O
O
O
OO
O
O O O
O
O
O
O
O
O
O
OMeOOC
HO
HO
MeOOC
O
HO HO
Pseudomannobioside
O
OMeOOC
HOHO
MeOOC
HO HO
OHO
HO
HO O
O
Pseudomannotrioside  
 
Figure 2. 3rd generation of a Boltorn type dendrimer with pseu-
domannobioside and pseudomannotrioside as ligands. 
 
 
 
Figure 3. A VLP functionalized with a nonavalent dendron of 
mannose. 
With the aim to mimic better the multivalent presentation of 
carbohydrates at the surface of pathogens to compete for DC-
SIGN, a virus like particle (VLP) was used as core to conju-
gate trivalent and nonavalent dendrons of mannoses in a con-
vergent synthetic strategy30. Using direct mutagenesis, an 
unnatural aminoacid, homopropargylglycine, replacing a me-
thionine, was introduced in the peptidic sequence of the mon-
omer QB protein. After a self-assembly process, a sphere-like 
icosahedron particle with a diameter of around 28 nm was 
obtained with 180 alkyne groups at the surface. These alkyne 
groups were conjugated via click copper-catalyzed alkyne-
azide cycloaddition (CuAAC) reaction with mannosylated 
dendrons of 1st and 2nd generation containing and azido group 
at the focal position to create the corresponding particles with 
540 and 1620 mannoses, respectively (Figure 3). This gly-
codendriproteins have a size in the same order of magnitude as 
the pathogens to be mimicked and display in a precise way a 
large number of ligands (mannoses) to interact in a very strong 
way to DC-SIGN. 
In the search for innovative scaffolds, we focused on un-
explored 3D fullerene C60 since it has a unique symmetrical 
and globular structure (1 nm of diameter) which makes it 
an interesting biocompatible carbon platform for the multi-
valent presentation of carbohydrates. Its high hydrophobi-
city can be avoided by the preparation of hexakis-adducts 
of [60]fullerene, as these compounds present six organic 
addends with a Th-symmetrical octahedral addition 
pattern.31 Hexakis-adducts of [60]fullerene are generally 
easily obtained by the Bingel-Hirsch addition of malonates 
to C60. One limitation of this synthesis is, however, the low 
yields obtained when the size of the added malonates in-
creases.32 To overcome this problem,  hexakis-adduct 2 
bearing six malonates appended with alkynes was synthe-
sized.33 This compound allowed the formation of “sugar 
balls” by using the efficient click CuAAC reaction. In this 
way, it is possible to obtain the carbohydrate-containing 
 [60]fullerene derivatives in two synthetic steps, as depicted 
in Scheme 1 with good to excellent yields.33-34 
The characterization of these compounds was carried out 
by the common analytical and spectroscopic techniques, 
being 13C NMR especially helpful. The 13C NMR spectra of 
hexakis-adducts of C60 show only two signals in the sp2 
region (δ  141 and 145) and only one signal for the sp3 
carbons (δ  69), thus allowing to have evidence of the 
formation of the highly symmetric octahedral derivative. 
For the completion of the click reaction, FTIR analyses 
were also valuable, as the typical bands for alkyne and 
azide groups (at  2117 and 2092 cm-1 respectively) ob-
served in the starting products are not present in the sugar 
derivatives, indicating the efficiency of the cycloaddition 
step. 
To check if this presentation of carbohydrates shows a 
multivalent effect, interaction of compounds 4a-b,d with 
Concanavalin A (Con A), a mannose recognizing lectin 
present in jack-beans, was studied by isothermal titration 
calorimetry (ITC). Indeed, an increase in the Ka was ob-served when going from the monovalent reference ligand 
(Me-Man, Ka  1.2·104 M-1) to the hexakis-adducts 4a 
(Ka  421·104 M-1) and 4d (Ka  137·104 M-1) bearing 24 
mannoses (4b substituted with galactoses was used as 
negative control and showed no interaction with Con A). 
Interestingly, if the ΔG values for 4a ( -9 kcal·mol-1) and 
4d ( -8.4 kcal·mol-1) are examined, the binding with Con 
A seemed to be more favorable in the case of 4a with a 
lower valency. These experimental findings were account-
ed for by the great entropic cost that has the binding be-
tween 4d and the lectin, and indicates that not only the 
number of ligands is important but also the distribution 
around the spherical platform of fullerene and the size of 
the linker between C60 and the sugars. 
The dynamics of glycofullerenes 4a and 4f has been in-
vestigated by NMR translational diffusion and quantitative 
13C relaxation studies.35 These studies show that the better 
activity of 4f in comparison to 4a (which differ in one order 
of magnitude for the IC50 values) may find explanation in its slower translational diffusion, thus facilitating rebinding 
to the receptor, together with the bigger spatial extension of 
the molecule, which would allow chelate binding to a sec-
ond receptor site.  
 
Scheme 1. Synthesis of fullerene sugar balls from alkyne append-
ed derivative 2. 
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Figure 4. Molecular structure of tridecafullerenes bearing 120 sugar moieties (left). Representative 13C NMR signals for compound 5a 
(right). 
 
To increase dramatically the valency and the size of the 
fullerene derivatives, new tridecafullerenes (5) – in which 
the central alkyne scaffold of [60]fullerene has been con-
nected to 10 sugar-containing [60]fullerene units – have 
been synthesized (Figure 4).36 The synthesis of these com-
pounds implies obtaining new [60]fullerene based building 
blocks carrying the carbohydrate moieties as well as an 
azide group for further functionalization, and they have 
been prepared with two different spacers between the cen-
tral fullerene and the peripheral C60 units. These azide containing glycofullerenes can be added under CuAAC 
conditions to the previously obtained hexakis-adduct 2 to 
yield the “super balls” formed by 13 [60]fullerene moieties 
covalently linked and surrounded by 120 carbohydrate 
ligands! This reaction has been described as the fastest 
dendrimer growing reported to date.37 
13C NMR characterization of these tridecafullerenes is 
again relevant, as only two of all the sp2 carbon atoms of 
the [60]fullerene are observed, revealing the octahedral 
symmetry of the hexakis-adduct (Figure 4). X-Ray Photoe-
lectron Spectroscopy (XPS) analysis of the compounds 
allowed identifying the nature and relative abundance of 
the atoms present in the molecule. Thus, these spectra show 
the C 1s, O 1s and N 1s features and the high resolution N 
1s core-level spectrum shows two components in a 1:2 
ratio, as expected from the triazole rings present in the 
structure of the molecules. Transmission Electron Micros-
copy (TEM) and Dynamic Light Scattering (DLS) experi-
ments show a 4-6 nm size for these tridecafullerenes. 
BIOLOGICAL ASSAYS 
To test the inhibitory properties of compounds on EBOV 
DC-SIGN-mediated infection we have used a system in 
which a T-lymphocyte cell line, one of the few cell popula-
tion resistant to EBOV infection19, is rendered susceptible 
by the expression of DC-SIGN21a.  In this system cell infec-
tion with an EBOV GP-pseudotyped viral particle is com-
pletely dependent on DC-SIGN since T-lymphocytes lack 
any other attachment receptors to facilitate EBOV cell 
entry.  On one hand, this model is very appropriate to have 
clean experiments and to demonstrate that the inhibition of 
tested molecules is based exclusively on the blockage of 
the receptor DC-SIGN. On the other hand, this model per-
mits the use of BSL2-3 laboratories, more accessible and 
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available all around to obtain results concerning the activity 
of the new candidates to inhibit Ebola infection at a reason-
able cost and in a short time.  As a control of the infection 
we used viral particles pseudotyped with the envelope 
glycoprotein of the vesicular stomatitis virus (VSV) that 
does infect T-lymphocytes in a DC-SIGN-independent 
manner21a. The 50% of inhibition of the infection (IC50) is typically calculated with 95% confidence intervals (IC95)38. Recombinant viruses are produced by co-transfection in 
producer cells of the viral glycoprotein along with the ret-
roviral backbone expressing firefly luciferase as the report-
er gene. The assay based on GP-pseudotyped viral particles 
has been extensively used for pathogenesis and antiviral 
screening by our group and others for different purposes 
and it has been compared with live viruses assays showing 
strong correlation38-39. 
Proof of concept of the capability of multivalent man-
nose glycoconjugates to compete with DC-SIGN for viral 
entry of EBOV-GP particles was obtained with relative 
simple dendrimeric compounds such as Boltorn derivates 
exhibiting 32 carbohydrate molecules with IC50 in the mi-cromolar to nanomolar range (depending on the ligand 
used)28b. Subsequently, in order to gain mannose multiva-
lency, the highly polyvalent bacteriophage-based gly-
codendrinanoparticle displaying 1620 copies of mannose 
on its surface achieved IC50 in the high picomolar range30. More recently, the synthesis of giant globular glycofuller-
enes 5 decorated with mannoses has also shown antiviral 
activity with IC50 in the subnanomolar range36. 
OUTLOOK AND PERSPECTIVES  
Emergent pathogenic viruses represent nowadays one of 
the most dangerous causes for diseases in the human being. 
In particular, Ebola virus since its first detection in 1976 
has been responsible for several outbreaks resulting in a 
great proportion of deaths1,40. The unprecedented magni-
tude of the last outbreak in West Africa (2013-6) and its 
global impact make it necessary to establish preparedness 
for future epidemics. 
In the search for new pathways for addressing Ebola vi-
rus infections, we have focused on the well-known carbo-
hydrate−protein interactions since they govern a wide vari-
ety of biological processes. Importantly, carbohy-
drate−protein interactions usually occur by means of the 
multivalent effect. In this regard, different chemical and 
bio-inspired scaffolds have been used in the literature in the 
search for new glycoconjugates bearing larger units of 
carbohydrates located in the right spatial arrangement. 
Within the development of our project, we have prepared 
mannosylated fullerenes containing several copies of car-
bohydrates in a globular presentation. These multivalent 
systems have a good solubility in aqueous media and a low 
cytotoxicity against several cell lines. Preliminary binding 
studies using the model lectin Concanavalin A demonstrat-
ed the potency of these glycodendrofullerenes to interact 
with lectins in a multivalent manner. In this regard, a varie-
ty of carbohydrate multivalent systems based on den-
drimers have been synthesized for the development of 
molecules capable to block DC-SIGN. In order to get a 3D 
globular scaffold thus resembling the most usual virus 
geometry, we were able to prepare, for the first time, new 
glycodendrofullerenes as antiviral agents. The antiviral 
activity of these compounds in an Ebola pseudotyped infec-
tion model were in the low micromolar range for fullerenes 
with 12 mannoses, a very promising data. Interestingly, the 
increase of valency to 36 mannoses in glycofullerene 4e 
induced a loss of antiviral effect. This could be probably 
related to steric congestion of sugars at the surface of the 
fullerene. One important factor to achieve high affinity in 
binding processes is not only the spatial presentation of the 
ligand but also the adequate accessibility of these ligands to 
interact with the corresponding receptor. Using a gly-
codendrofullerene showing the same valency as compound 
4e, but including a longer spacer, we have increased re-
markably the inhibitory activity of these compounds with 
IC50 values in the low micromolar range, probably due to a more efficient interaction with DC-SIGN. This result high-
lights the importance to combine an adequate scaffold to 
achieve the multivalency (the spherical [60]fullerene) with 
the right ligand presentation in terms of accessibility and 
flexibility. The valency of the compound is an important 
factor to obtain good affinities in a carbohydrate−lectin 
interaction but, as it has been shown in these experiments, 
it is not the only factor to be taken into account. 
More recently, the synthesis of giant globular glycofull-
erenes decorated with mannoses (sugar superballs) have 
been synthesized and characterized by a variety of tech-
niques. Interestingly, the so-called tridecafullerenes deco-
rated with 120 mannoses have also shown antiviral activity 
with IC50 in the subnanomolar range. These experimental 
findings make these sugar superballs the most active mole-
cules to inhibit the Ebola virus infection reported so far. 
Based on the aforementioned results, fullerenes should 
be considered as very attractive and compatible 3D scaf-
folds for a globular multivalent presentation of sugars. 
These promising results prompt us to the search for new 
approaches for the design and preparation of glycodendritic 
key building blocks to conjugate on fullerenes. An im-
portant concept is, however, a fine control of the conges-
tion between carbohydrates to prevent unfavorable steric 
hindrances in the search for better antiviral activities. 
Needless to say that currently there are a great variety of 
known carbon nanoforms which could also be used as 
potential scaffolds for the multivalent presentation of car-
bohydrates,41 namely single and multiwall carbon nano-
tubes, graphene or graphene quantum dots where the con-
trol of the carbohydrate functionalization and distribution 
still represents a future scientific challenge. This is also 
applicable to the variety of potential carbohydrates, both in 
terms of their own nature (monosaccharides, disaccharides, 
polysaccharides, etc.) and number of units (monomer, 
dimer, trimer, etc.). A combination of more efficient lig-
ands and more adequate presentation on different scaffolds 
should eventually afford a variety of lead hybrid molecules 
with higher specificity and efficiency on Ebola virus infec-
tion. 
A final consideration is that, although some vaccines are 
currently under study for the Ebola virus, the availability of 
chemical compounds able to fight against Ebola virus at 
different stages of the infective process  are scarce and 
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preliminary results of clinical efficacy have been 
limited10a,10b,39,42. The multivalent presentation of specific 
carbohydrates by using 3D fullerenes as controlled bio-
compatible carbon scaffolds represents a real advance, 
which, however, requires more studies to determine the 
optimized leads for practical purposes. The pathway is 
open and the only limitation to this goal is the imagination 
of the chemists. 
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